New FDA Approval: Immunomedics
New FDA Approval: Immunomedics
Trodelvy
May, 2020
Immunomedics is proud to announce that the U.S. Food and Drug Administration (FDA) has approved Trodelvy™ (sacituzumab govitecan-hziy)for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC)who have received at least two prior therapies for metastatic disease.Trodelvyis the first ADC approved bytheFDAspecifically for relapsedor refractorymetastatic TNBCand is also the first FDA-approved anti-Trop-2 ADC.
To read the full announcement, please click this link.
